A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
NCT ID: NCT02611492
Last Updated: 2019-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
265 participants
INTERVENTIONAL
2016-04-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
NCT00702403
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084
Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
NCT02201459
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intensive Arm (A)
4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
\+ Post-SCT Maintenance
Nilotinib
400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
Methotrexate
1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Aracytine (Ara C)
Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
Granulocyte Colony-Stimulating Factor (G-CSF)
5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
Depomedrol
40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
Dexamethasone
40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
Vincristine
2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
Imatinib
300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
6 Mercaptopurine (6MP)
60 mg/m2 per os, D1 to D14, interphase
Light Arm (B)
4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
\+ Post-SCT Maintenance
Nilotinib
400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
Methotrexate
1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Granulocyte Colony-Stimulating Factor (G-CSF)
5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
Depomedrol
40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
Dexamethasone
40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
Vincristine
2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
Imatinib
300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
6 Mercaptopurine (6MP)
60 mg/m2 per os, D1 to D14, interphase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nilotinib
400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
Methotrexate
1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Aracytine (Ara C)
Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
Granulocyte Colony-Stimulating Factor (G-CSF)
5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
Depomedrol
40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
Dexamethasone
40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
Vincristine
2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
Imatinib
300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
6 Mercaptopurine (6MP)
60 mg/m2 per os, D1 to D14, interphase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Whose blood and bone marrow explorations have been completed before the steroids prephase
2. Aged 18-59 years old with newly-diagnosed non previously treated Ph+ ALL according to WHO 2008 criteria (confirmed diagnosis of the Philadelphia chromosome defined by the reciprocal translocation of chromosomes 9 and 22, t(9;22) and/or presence of the BCR-ABL molecular maker)
3. With ≥ 20% bone marrow blasts
4. With Eastern Cooperative Oncology Group (ECOG) Performans Status ≤ 3
5. With or without central nervous system (CNS) or testis involvement
6. Without evolving cancer (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix) or its chemo- or radio-therapy should be finished at least since 6 months.
7. Having received no previous treatment for this hematological disease (including IT injection)
8. Having signed written informed consent
9. With efficient contraception for women of childbearing age (excluding estrogens and IUD)
10. With health insurance coverage
11. Who have received (or being receiving) the recommended steroid prephase.
Note 1: Secondary ALL (antecedent of chemo- or radio-therapy) can be included Note 2: In case of high vascular risk (see section "study management") the patient will not be able to receive nilotinib unless an ultra sound Doppler of the neck and lower limbs has been performed during the pre-phase and treatment validated by the medical coordinators of the protocol via the secretariat.
Exclusion Criteria
1. Previously treated with Tyrosine Kinase Inhibitor (TKI)
2. With another active malignancy
3. With general or visceral contra-indication to intensive therapy (except if considered related to the ALL):
1. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 x upper limit of normal range (ULN)
2. Total bilirubin \> 1.5 x ULN
3. Creatinine \> 1.5 x ULN or creatinine clearance \<50 mL/mn
4. Serum amylase or lipase \> 1.5 x ULN or antecedents of acute pancreatitis
4. With heart failure, including at least one of the following criteria:
1. Left ventricular ejection fraction (LVEF) \<50% or below the lowest normal threshold, as determined by ECG or heart failure (NYHA grade III or IV)
2. Impossibility to measure the QT interval on ECG
3. Complete left bundle branch block
4. Pacemaker
5. Congenital long QT syndrome of known familial antecedents of long QT syndrome
6. Antecedents or current ventricular or atrial tachyarrhythmia, clinically significant
7. Baseline bradycardia (\<50 bpm) clinically significant
8. Corrected QT interval (QTc)\> 450 msec established on the mean of 3 baseline ECG
9. Antecedents of myocardial infarct in the past 6 months
10. Instable angor within the past 12 months
11. Any heart condition clinically significant (i.e. congestive heart failure, uncontrolled hypertension)
5. Active uncontrolled infection, any other concurrent disease deemed to interfere with the conduct of the study as judged by the investigator
6. Severe evolving infection, or known HIV or Human T-Lymphotropic Virus type I (HTLV1) seropositivity, or active infection by hepatitis B or C virus
7. Pregnant (beta-HCG) or nursing woman
8. Women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter. Patient not willing to ensure not to beget a child during participation in the study and at least three months thereafter.
9. Having received an investigational treatment or participation in another trial within 30 days prior to entering this study.
10. Not able to bear with the procedures or the frequency of visits planned in the trial.
11. Unable to consent, under tutelage or curators, or judiciary safeguard
18 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Saint Louis
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chalandon Y, Rousselot P, Chevret S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Guepin GR, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lheritier V, Clappier E, Boissel N, Dombret H. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood. 2024 Jun 6;143(23):2363-2372. doi: 10.1182/blood.2023023502.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOM12629_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.